Accustem Sciences Reports Q1 Loss, Critically Low Cash, and Immediate Liquidity Crisis

summarizeSummary

Accustem Sciences Inc. reported a Q1 net loss of $(485,883) with zero revenue, a cash balance of only $12,207, and a stated cash runway that expires this month, signaling an immediate and severe liquidity crisis.

check_boxKey Events

• Immediate Liquidity Crisis

  The company's cash balance is critically low at $12,207 as of March 31, 2026, with management explicitly stating funds are only sufficient to cover operations until May 2026.

• Continued Operating Losses

  Accustem Sciences reported a net loss of $(485,883) for Q1 2026 with zero revenue, increasing the accumulated deficit to over $10.2 million.

• Going Concern Warning

  The company continues to operate under a going concern warning, emphasizing the uncertainty of its ability to continue as a viable entity without immediate financing.

• Material Weakness in Controls

  Management identified a material weakness in internal controls over financial reporting due to a lack of accounting resources, which persists from prior periods.

auto_awesomeAnalysis

Accustem Sciences Inc. has reported a net loss of $(485,883) for Q1 2026 with zero revenue, exacerbating its severe financial distress. The company's cash balance has dwindled to $12,207, and management explicitly states that existing cash is only sufficient to fund operations until May 2026, indicating an immediate and critical liquidity crisis. This follows a prior going concern warning and highlights the urgent need for significant additional capital to continue operations. The company also continues to report a material weakness in internal controls.